Skip to Content

Research Highlights

There have been many research highlights resulting from the GMP. A selection of these are listed below.

Epidemic Prediction Women sewing bed net

  • Development of a district based system for epidemic prediction in Kenya and Uganda

Vector Control 

  • Development of collaborative research programmes with agrochemical companies on the identification and evaluation of  alternatives to pyrethroids for treatment of nets and other materials. 
  • Development of a new, simple means of converting untreated bednets into long-lasting insecticide treated bednets. Demonstration of the efficacy of the combined use of insect repellents and insecticide treated bednets

 Chemoprevention and treatment

  • Demonstration of a substantial effect on morbidity from malaria of monthly intermittent preventive treatment with SP and artesunate in children aged  6-59 months in an area of seasonal malaria transmission in Senegal
  • Demonstration that intermittent  preventive treatment with SP may not be necessary for the effective prevention of malaria in HIV negative multigravidae
  • Development of a system for the evaluation of new anti-malarials in pregnancy and demonstration of the efficacy of SP and amodiaquine in treating pregnant women in Ghana
  • Demonstration that the use of rapid diagnostic tests for the diagnosis of malaria does not stop prescription of antimalarial drugs to large numbers of patients who do not have malaria

Vaccine development

  • Identification of a specific variant (VAR2CSA) of the P. falciparum multigene family of proteins PfEMP1 in most parasites isolated from the placenta making it a possible  vaccine candidate for use in pregnancy
  • Demonstration of the potential value of PCR  diagnosis of  malaria as a way of reducing the size and duration of malaria vaccine trials
  • Demonstration that the malaria vaccine  RTS,S/ASO2A does not select  for parasites of  non-vaccine  genotype

Economic and social studies

  • Demonstration that households in The Gambia spend a considerable amount of money on a range of malaria prevention measures but  that few of them buy bednets as they are considered too expensive
  • Demonstration that families in Tanzania are willing to pay more for effective artemisinin based drug combinations than for less effective drugs, but not the true cost of the drugs
  • Demonstration that intermittent  preventive treatment with SP delivered with EPI was well received and did not reduce acceptance of the vaccines

 Research into practice

  • Facilitation of wide scale implementation of the HIMAL malaria epidemic prediction and detection system in Kenya and Uganda, with support from GFATM
  • Provision of support for the implementation and evaluation of the Tanzanian voucher scheme
  • Demonstration that when used in routine practice Co-Artem is a highly effective treatment for uncomplicated malaria in areas with a high level of resistance to alternative drugs
  •  Provision of support for two drug sensitivity testing networks (WANMAT 1 and WANMAT 2) in West Africa which provide local advice on best treatment practice